Podoplanin drives dedifferentiation and amoeboid invasion of melanoma
Authors:
- Charlotte M. de WindeCWCharlotte M. de Winde
- Samantha L. GeorgeSGSamantha L. George
- Abbey B. ArpAAAbbey B. Arp
- Agnesska C. BenjaminABAgnesska C. Benjamin
- Eva Crosas-MolistECEva Crosas-Molist
- Yukti Hari-GuptaYHYukti Hari-Gupta
- Alexander CarverACAlexander Carver
- Valerio ImperatoreVIValerio Imperatore
- Victor G. MartinezVMVictor G. Martinez
- Victoria Sanz-MorenoVSVictoria Sanz-Moreno
- Sophie E. ActonSASophie E. Acton
Preprint
Abstract
Melanoma is an aggressive skin cancer developing from melanocytes, frequently resulting in metastatic disease. Melanoma cells utilise amoeboid migration as mode of local invasion. Amoeboid invasion is characterized by rounded cell morphology and high actomyosin contractility driven by the RhoA signalling pathway. Migrastatic drugs targeting actin polymerization and contractility to inhibit invasion and metastasis are therefore a promising treatment option. To predict amoeboid invasion and metastatic potential, there is a need for biomarkers functionally linked to contractility pathways. The glycoprotein podoplanin drives actomyosin contractility in lymphoid fibroblasts, and is overexpressed in several cancer types. Here, we show that podoplanin enhances amoeboid invasion in melanoma. Expression of podoplanin in murine melanoma models drives rounded cell morphology, increasing motility and invasion in vivo . Podoplanin expression is upregulated in a subset of dedifferentiated human melanoma, and in vitro is sufficient to suppress melanogenesis and upregulate melanoma-associated markers Mitf and Pou3f2 . Together, our data indicates that podoplanin is both a potential biomarker for dedifferentiated invasive melanoma and a promising migrastatic therapeutic target.Keywords
All Related Versions
- Published version: iScience, 24 (9), 102976.
This publication has 20 references indexed in Scilit:
- Treatment of Advanced Melanoma in 2020 and BeyondJournal of Investigative Dermatology, 2021
- BRN2, a POUerful driver of melanoma phenotype switching and metastasisPigment Cell & Melanoma Research, 2018
- Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and ChallengesTrends in Cancer, 2017
- Emerging Biological Principles of MetastasisCell, 2017
- Modes of invasion during tumour disseminationMolecular Oncology, 2016
- The roles of microphthalmia-associated transcription factor and pigmentation in melanomaArchives of Biochemistry and Biophysics, 2014
- Matrix geometry determines optimal cancer cell migration strategy and modulates response to interventionsNature Cell Biology, 2013
- Intravital Imaging Reveals Transient Changes in Pigment Production and Brn2 Expression during Metastatic Melanoma DisseminationCancer Research, 2009
- Melanoma biology and new targeted therapyNature, 2007
- ROCK- and Myosin-Dependent Matrix Deformation Enables Protease-Independent Tumor-Cell Invasion In VivoCurrent Biology, 2006